---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-26T21:55:34.325918'
end_time: '2025-12-26T22:02:10.379346'
duration_seconds: 396.05
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: WFS1
  gene_symbol: WFS1
  uniprot_accession: O76024
  protein_description: 'RecName: Full=Wolframin;'
  gene_info: Name=WFS1;
  organism_full: Homo sapiens (Human).
  protein_family: Not specified in UniProt
  protein_domains: TPR-like_helical_dom_sf. (IPR011990); Wolframin. (IPR026208); Wolframin_Cys-rich.
    (IPR045400); Wolframin_EF-hand. (IPR045460); Wolframin_fam. (IPR026209)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 28
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** O76024
- **Protein Description:** RecName: Full=Wolframin;
- **Gene Information:** Name=WFS1;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** TPR-like_helical_dom_sf. (IPR011990); Wolframin. (IPR026208); Wolframin_Cys-rich. (IPR045400); Wolframin_EF-hand. (IPR045460); Wolframin_fam. (IPR026209)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "WFS1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'WFS1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **WFS1** (gene ID: WFS1, UniProt: O76024) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** O76024
- **Protein Description:** RecName: Full=Wolframin;
- **Gene Information:** Name=WFS1;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** TPR-like_helical_dom_sf. (IPR011990); Wolframin. (IPR026208); Wolframin_Cys-rich. (IPR045400); Wolframin_EF-hand. (IPR045460); Wolframin_fam. (IPR026209)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "WFS1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'WFS1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **WFS1** (gene ID: WFS1, UniProt: O76024) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research plan and target verification
We verified the target as human WFS1 (UniProt O76024), encoding wolframin, an endoplasmic reticulum (ER) multi-pass membrane protein localized to ER and mitochondria-associated ER membranes (MAMs). Recent human-cell and mammalian model studies consistently describe WFS1 as ER/MAM-resident and central to ER Ca2+ homeostasis and unfolded protein response (UPR) regulation, aligning with the UniProt description and domain-level inferences (e.g., luminal Ca2+-related features), with no ambiguity to other similarly named genes in different organisms (pseudonym “wolframin”). This confirms the correct gene/protein and organism context for research below (liiv2024ercalciumdepletion pages 1-2, patergnani2024thewolframlikevariant pages 1-6).

Key concepts and definitions with current understanding
- Molecular identity and localization: WFS1/wolframin is an ER transmembrane protein enriched at MAMs, where it supports ER–mitochondria Ca2+ coupling. Loss or pathogenic variants reduce ER–mitochondria contacts and impair Ca2+ transfer, producing mitochondrial bioenergetic failure (reduced OXPHOS/ATP) and compensatory autophagy/mitophagy (Nature Communications, 2024; Autophagy, 2024) (liiv2024ercalciumdepletion pages 1-2, patergnani2024thewolframlikevariant pages 1-6, patergnani2024thewolframlikevariant pages 6-9). URL and date: https://doi.org/10.1038/s41467-024-50502-x (Jul 2024); https://doi.org/10.1080/15548627.2024.2341588 (Apr 2024).
- Core function in ER Ca2+ handling: In primary neurons, WFS1 deficiency causes ER Ca2+ depletion, fewer MAMs, reduced IP3R-mediated ER→mitochondria Ca2+ transfer, and decreased mitochondrial matrix Ca2+. Consequences include reduced ATP production, increased NADH/NAD+ ratio (reductive stress), and neuronal vulnerability (Nat Commun 2024) (liiv2024ercalciumdepletion pages 1-2, liiv2024ercalciumdepletion pages 9-12). URL and date: https://doi.org/10.1038/s41467-024-50502-x (Jul 2024).
- UPR/ATF6 regulation: WFS1 acts as a negative regulator of the UPR, particularly ATF6 signaling; loss of WFS1 promotes excessive ATF6 activation with downstream pro-apoptotic and stress gene induction. This mechanistic role of WFS1 in attenuating ATF6-driven ER stress is reiterated in 2024 summaries and reviews (preprint), consistent with prior foundational literature (caruso2024beyondwolframsyndromea pages 7-9, morikawa2024comprehensiveoverviewof pages 11-13). URL and date: https://doi.org/10.20944/preprints202409.2402.v1 (Sep 2024); https://doi.org/10.1007/s00335-023-10028-x (Feb 2024).
- Interacting partners and complexes: In neurons, WFS1 biochemically associates with CISD2, SERCA2, and RyR2; functionally, WFS1/CISD2 co-regulate ER Ca2+ content, MAM integrity, and IP3R-mediated Ca2+ transfer. Rescue experiments highlight SERCA2b and MAM tethers (e.g., GRP75) as modulators downstream of WFS1 (Nat Commun 2024) (liiv2024ercalciumdepletion pages 9-12). URL and date: https://doi.org/10.1038/s41467-024-50502-x (Jul 2024).

Recent developments and latest research (prioritizing 2023–2024)
- ER Ca2+ depletion as the proximal driver in WS neurons: Liiv et al. (2024) show ER Ca2+ loss in WFS1- or CISD2-deficient primary neurons drives reduced ER→mitochondria Ca2+ transfer, mitochondrial depolarization, decreased ATP, and reductive stress. Mechanistic rescues included SERCA2b overexpression or SERCA activation (CDN1163 0.5 μM) restoring ER/axoplasmic Ca2+; suppressing SERCA via phospholamban recapitulated the disease phenotype. Additional modulators (GRP75 overexpression, RyR2 suppression, IP3R1 overexpression) restored Ca2+ fluxes and ATP in neuronal axons (liiv2024ercalciumdepletion pages 1-2, liiv2024ercalciumdepletion pages 9-12). URL and date: https://doi.org/10.1038/s41467-024-50502-x (Jul 2024).
- MAM destabilization and mitochondrial quality-control defects in a human Wolfram-like variant: Patergnani et al. (2024) demonstrate that WFS1E864K (human and mouse) reduces ER–mitochondria contacts by 62% in cortex (TEM; p=0.0042), reduces mitochondrial Ca2+ uptake, lowers basal/ATP-linked/maximal respiration (Seahorse), and increases autophagy/mitophagy markers (elevated LC3-II, p62; increased GFP-LC3 puncta; mitotracker–lysotracker colocalization). These data position WFS1-related disease as a MAMopathy (patergnani2024thewolframlikevariant pages 6-9, patergnani2024thewolframlikevariant pages 1-6). URL and date: https://doi.org/10.1080/15548627.2024.2341588 (Apr 2024).
- ISR inhibition rescues β-cell failure: Hu et al. (2024) show that integrated stress response inhibitor ISRIB restores β-cell function in human WFS1−/− stem cell-derived islets and in vivo Wfs1 conditional knockout mice: ISRIB increased INS-GFP+/NKX6.1+ β-cell proportion, reduced stress-granule marker G3BP1, restored global protein synthesis, reduced Annexin V+ apoptosis, and rescued insulin content/β-cell mass with improved glucose tolerance in mice (hu2024isrinhibitionreverses pages 7-10). URL and date: https://doi.org/10.1038/s41418-024-01258-w (Feb 2024).
- Genotype–phenotype and variant classes: Wu et al. (2024) identified compound heterozygous WFS1 variants in early-onset diabetes; frameshift p.A214fs*74 eliminated wolframin, and missense p.I427S nearly eliminated expression in HEK cells. Patients exhibited Wolfram-spectrum diabetes without classic DI/OA features, indicating that variant class and location (exon 8 enriched) influence protein expression and phenotype, risking misdiagnosis (wu2024novelwfs1variants pages 3-6). URL and date: https://doi.org/10.3389/fgene.2024.1433060 (Aug 2024). Complementary review of models and variant impacts is provided by Morikawa et al. (2024) (morikawa2024comprehensiveoverviewof pages 11-13). URL and date: https://doi.org/10.1007/s00335-023-10028-x (Feb 2024).
- Optic neuropathy and white-matter involvement: Contemporary studies link WFS1 dysfunction to optic nerve axonal mitochondrial deficits and retinal ganglion cell injury; MAM loss and altered mitophagy are implicated in Wolfram-like optic atrophy models (2024–2025). While oligodendroglial contributions are under investigation, convergent data indicate axonal bioenergetic failure and neuroinflammation in optic pathways (Autophagy, 2024; related preprints, 2025) (patergnani2024thewolframlikevariant pages 1-6, dieguez2025wfs1e864kinhumans pages 41-44). URLs and dates: https://doi.org/10.1080/15548627.2024.2341588 (Apr 2024); https://doi.org/10.1101/2025.10.13.682105 (Oct 2025).

Current applications and real-world implementations
- GLP-1 receptor agonists: A 2024 overview (Morikawa et al.) summarizes preclinical evidence that GLP-1R agonists improve glucose tolerance in WS models; liraglutide prevented glucose intolerance, reduced neuroinflammation, protected retinal ganglion cells, and delayed hearing/vision loss in Wfs1 mutant rats. These data support off-label exploration and future trials in WS (morikawa2024comprehensiveoverviewof pages 11-13). URL and date: https://doi.org/10.1007/s00335-023-10028-x (Feb 2024).
- ER Ca2+ stabilizers and UPR modulators: Dantrolene (RyR inhibitor) advanced to a phase Ib/IIa clinical trial in WS; chemical chaperones (PBA, TUDCA) and sodium valproate (HDAC inhibitor) have been explored to mitigate ER stress and increase WFS1 expression; a placebo-controlled phase II trial of valproate in WS is listed (Jurca 2024 review) (jurca2024wolframsyndrometype pages 11-12, jurca2024wolframsyndrometype pages 15-16). Trial registry and review URL/dates: https://doi.org/10.3390/medicina60071064 (Jun 2024). (Jurca cites NCT03717909; check registry for current status.)
- ISR inhibition as a candidate therapeutic: ISRIB showed robust rescue of β-cell defects in WS models (Cell Death & Differentiation, 2024), nominating ISR targeting as a translational strategy; safety and systemic effects remain to be addressed clinically (hu2024isrinhibitionreverses pages 7-10). URL and date: https://doi.org/10.1038/s41418-024-01258-w (Feb 2024).

Expert opinions and analysis from authoritative sources
- Framing WFS1 disease as a MAMopathy: 2024 primary studies position WFS1 deficiency and certain missense variants (e.g., E864K) within a MAM-centric pathophysiology with quantifiable loss of ER–mitochondria contacts and Ca2+ coupling, leading to mitochondrial dysfunction and activation of autophagy/mitophagy. This refined model provides mechanism-based biomarkers and interventional points (SERCA activation, RyR/IP3R modulation, MAM tether enhancement) (liiv2024ercalciumdepletion pages 1-2, patergnani2024thewolframlikevariant pages 1-6, patergnani2024thewolframlikevariant pages 6-9). URLs/dates: https://doi.org/10.1038/s41467-024-50502-x (Jul 2024); https://doi.org/10.1080/15548627.2024.2341588 (Apr 2024).
- UPR/ATF6 axis in WS: Contemporary analyses reiterate WFS1’s attenuation of ATF6 signaling, supporting a combined Ca2+-UPR model in which ER Ca2+ depletion and unrestrained ATF6 activation drive β-cell and neuronal vulnerability. This informs rationale for ISR/UPR-targeted therapies (caruso2024beyondwolframsyndromea pages 7-9, morikawa2024comprehensiveoverviewof pages 11-13). URLs/dates: https://doi.org/10.20944/preprints202409.2402.v1 (Sep 2024); https://doi.org/10.1007/s00335-023-10028-x (Feb 2024).

Relevant statistics and data from recent studies
- ER–mitochondria contact and mitochondrial function: WFS1E864K mice showed a 62% reduction in ER–mitochondria contacts by TEM in cortex (p=0.0042), reduced mitochondrial Ca2+ uptake (p<0.0001 to 0.0022 depending on assay), and significantly reduced basal/ATP-linked/maximal respiration (Autophagy, 2024) (patergnani2024thewolframlikevariant pages 6-9). URL and date: https://doi.org/10.1080/15548627.2024.2341588 (Apr 2024).
- Neuronal ER Ca2+ and bioenergetics: WFS1/CISD2 deficiency in primary neurons leads to ER Ca2+ depletion, lower IP3R-mediated Ca2+ flux to mitochondria, decreased mitochondrial Ca2+, reduced ATP, and increased NADH/NAD+ ratio; SERCA activation with CDN1163 (0.5 μM) and SERCA2b overexpression restored ER and axoplasmic Ca2+ to normal ranges; GRP75 overexpression and RyR2 suppression improved ER→mitochondria coupling and ATP production (Nat Commun, 2024) (liiv2024ercalciumdepletion pages 1-2, liiv2024ercalciumdepletion pages 9-12). URL and date: https://doi.org/10.1038/s41467-024-50502-x (Jul 2024).
- β-cell rescue by ISR inhibition: ISRIB increased INS-GFP+/NKX6.1+ β-cell fractions, reduced G3BP1 intensity (stress granules), restored protein synthesis, reduced Annexin V+ apoptosis, and restored insulin content and β-cell mass with improved glucose tolerance in Wfs1 β-cell CKO mice (Cell Death & Differentiation, 2024) (hu2024isrinhibitionreverses pages 7-10). URL and date: https://doi.org/10.1038/s41418-024-01258-w (Feb 2024).
- Genotype–phenotype quantitative effects on protein: Frameshift p.A214fs*74 produced absent wolframin protein; missense p.I427S nearly abolished expression in HEK cells; compound heterozygous combinations also markedly reduced expression, correlating with early-onset diabetes absent classic DIDMOAD features (Front Genet, 2024) (wu2024novelwfs1variants pages 3-6). URL and date: https://doi.org/10.3389/fgene.2024.1433060 (Aug 2024).

Mechanistic pathway synthesis
WFS1 maintains ER Ca2+ content and MAM architecture to sustain IP3R-mediated ER→mitochondria Ca2+ transfer, supporting mitochondrial dehydrogenases and ATP production in energetically demanding compartments such as axons and β-cells. WFS1 interacts functionally with SERCA and RyR to tune ER Ca2+ refilling and leak; loss of WFS1 causes ER Ca2+ depletion, fewer MAMs, and reduced mitochondrial Ca2+ uptake, triggering bioenergetic failure and activation of autophagy/mitophagy. In parallel, WFS1 attenuates UPR signaling, particularly ATF6; unchecked ER stress and ISR activation contribute to apoptosis and functional failure. Therapeutically, restoring ER Ca2+ (SERCA activation; RyR/IP3R modulation), reinforcing MAMs (e.g., GRP75), or dampening stress responses (ISRIB; chemical chaperones; valproate) are convergent strategies; GLP-1R agonists add β-cell and neuroprotective benefits in models (liiv2024ercalciumdepletion pages 1-2, liiv2024ercalciumdepletion pages 9-12, patergnani2024thewolframlikevariant pages 1-6, patergnani2024thewolframlikevariant pages 6-9, hu2024isrinhibitionreverses pages 7-10, morikawa2024comprehensiveoverviewof pages 11-13, jurca2024wolframsyndrometype pages 11-12).

Limitations and open questions
- Translation to clinic: While dantrolene reached early-phase trials and valproate is under evaluation, robust randomized clinical evidence for disease modification in neurological endpoints is lacking. ISR inhibitors have strong preclinical effects but need clinical safety/efficacy data. GLP-1R agonists show promise preclinically; controlled WS trials are needed (hu2024isrinhibitionreverses pages 7-10, morikawa2024comprehensiveoverviewof pages 11-13, jurca2024wolframsyndrometype pages 11-12, jurca2024wolframsyndrometype pages 15-16).
- Cell-type specificity: Emerging data emphasize axonal ER/MAM biology and optic neuropathy; the degree of oligodendroglial involvement versus primary axonal defects remains to be resolved with cell-type specific models (patergnani2024thewolframlikevariant pages 1-6, dieguez2025wfs1e864kinhumans pages 41-44).

Selected sources with URLs and dates
- Liiv et al., Nature Communications, ER Ca2+ depletion drives ER–mitochondria Ca2+ and mitochondrial dysfunction in WS; mechanistic rescues (Jul 2024): https://doi.org/10.1038/s41467-024-50502-x (liiv2024ercalciumdepletion pages 1-2, liiv2024ercalciumdepletion pages 9-12).
- Patergnani et al., Autophagy, WFS1E864K destabilizes MAM; increased autophagy/mitophagy; respiration defects (Apr 2024): https://doi.org/10.1080/15548627.2024.2341588 (patergnani2024thewolframlikevariant pages 1-6, patergnani2024thewolframlikevariant pages 6-9).
- Hu et al., Cell Death & Differentiation, ISRIB reverses β-cell failure in WS models (Feb 2024): https://doi.org/10.1038/s41418-024-01258-w (hu2024isrinhibitionreverses pages 7-10).
- Morikawa et al., Mammalian Genome, Disease models and translational strategies; GLP-1RA benefits in Wfs1 models (Feb 2024): https://doi.org/10.1007/s00335-023-10028-x (morikawa2024comprehensiveoverviewof pages 11-13, morikawa2024comprehensiveoverviewof pages 7-9, morikawa2024comprehensiveoverviewof pages 17-19).
- Wu et al., Frontiers in Genetics, Novel WFS1 variants and protein-level impacts (Aug 2024): https://doi.org/10.3389/fgene.2024.1433060 (wu2024novelwfs1variants pages 3-6).
- Jurca et al., Medicina, Clinical overview with trials and repurposing (valproate, GLP‑1RA) (Jun 2024): https://doi.org/10.3390/medicina60071064 (jurca2024wolframsyndrometype pages 11-12, jurca2024wolframsyndrometype pages 15-16).
- Caruso & Rigoli, Preprints.org, WFS1 negative regulation of ATF6 and ER stress signaling (Sep 2024): https://doi.org/10.20944/preprints202409.2402.v1 (caruso2024beyondwolframsyndromea pages 7-9).
- Dieguez et al., bioRxiv, WFS1E864K optic atrophy via axonal mitochondrial dysfunction (Oct 2025; mechanistic concordance) (dieguez2025wfs1e864kinhumans pages 41-44): https://doi.org/10.1101/2025.10.13.682105.

Conclusion
Human WFS1 (wolframin) is an ER/MAM protein essential for ER Ca2+ content, ER–mitochondria coupling, and controlled UPR/ATF6 signaling. 2023–2024 studies resolve ER Ca2+ depletion and MAM destabilization as proximal defects driving mitochondrial dysfunction, autophagy/mitophagy activation, and neuronal/β-cell failure. Translationally, ISR inhibition, GLP‑1 receptor agonists, ER Ca2+ stabilizers, and stress-modulating agents (e.g., valproate) represent convergent strategies built on this mechanism, with ISRIB showing strong β-cell rescue preclinically and GLP‑1RAs showing neuro-metabolic benefits in models. Pending clinical validation, these mechanism-guided approaches offer a path to disease modification in Wolfram syndrome and WFS1-related disorders (liiv2024ercalciumdepletion pages 1-2, liiv2024ercalciumdepletion pages 9-12, patergnani2024thewolframlikevariant pages 1-6, patergnani2024thewolframlikevariant pages 6-9, hu2024isrinhibitionreverses pages 7-10, morikawa2024comprehensiveoverviewof pages 11-13, jurca2024wolframsyndrometype pages 11-12, jurca2024wolframsyndrometype pages 15-16, wu2024novelwfs1variants pages 3-6, caruso2024beyondwolframsyndromea pages 7-9).

References

1. (liiv2024ercalciumdepletion pages 1-2): Mailis Liiv, Annika Vaarmann, Dzhamilja Safiulina, Vinay Choubey, Ruby Gupta, Malle Kuum, Lucia Janickova, Zuzana Hodurova, Michal Cagalinec, Akbar Zeb, Miriam A. Hickey, Yi-Long Huang, Nana Gogichaishvili, Merle Mandel, Mario Plaas, Eero Vasar, Jens Loncke, Tim Vervliet, Ting-Fen Tsai, Geert Bultynck, Vladimir Veksler, and Allen Kaasik. Er calcium depletion as a key driver for impaired er-to-mitochondria calcium transfer and mitochondrial dysfunction in wolfram syndrome. Nature Communications, Jul 2024. URL: https://doi.org/10.1038/s41467-024-50502-x, doi:10.1038/s41467-024-50502-x. This article has 41 citations and is from a highest quality peer-reviewed journal.

2. (patergnani2024thewolframlikevariant pages 1-6): Simone Patergnani, Méghane S. Bataillard, Alberto Danese, Stacy Alves, Chantal Cazevieille, René Valéro, Lisbeth Tranebjærg, Tangui Maurice, Paolo Pinton, Benjamin Delprat, and Elodie M. Richard. The wolfram-like variant wfs1 <sup>e864k</sup> destabilizes mam and compromises autophagy and mitophagy in human and mice. Autophagy, 20:2055-2066, Apr 2024. URL: https://doi.org/10.1080/15548627.2024.2341588, doi:10.1080/15548627.2024.2341588. This article has 15 citations and is from a domain leading peer-reviewed journal.

3. (patergnani2024thewolframlikevariant pages 6-9): Simone Patergnani, Méghane S. Bataillard, Alberto Danese, Stacy Alves, Chantal Cazevieille, René Valéro, Lisbeth Tranebjærg, Tangui Maurice, Paolo Pinton, Benjamin Delprat, and Elodie M. Richard. The wolfram-like variant wfs1 <sup>e864k</sup> destabilizes mam and compromises autophagy and mitophagy in human and mice. Autophagy, 20:2055-2066, Apr 2024. URL: https://doi.org/10.1080/15548627.2024.2341588, doi:10.1080/15548627.2024.2341588. This article has 15 citations and is from a domain leading peer-reviewed journal.

4. (liiv2024ercalciumdepletion pages 9-12): Mailis Liiv, Annika Vaarmann, Dzhamilja Safiulina, Vinay Choubey, Ruby Gupta, Malle Kuum, Lucia Janickova, Zuzana Hodurova, Michal Cagalinec, Akbar Zeb, Miriam A. Hickey, Yi-Long Huang, Nana Gogichaishvili, Merle Mandel, Mario Plaas, Eero Vasar, Jens Loncke, Tim Vervliet, Ting-Fen Tsai, Geert Bultynck, Vladimir Veksler, and Allen Kaasik. Er calcium depletion as a key driver for impaired er-to-mitochondria calcium transfer and mitochondrial dysfunction in wolfram syndrome. Nature Communications, Jul 2024. URL: https://doi.org/10.1038/s41467-024-50502-x, doi:10.1038/s41467-024-50502-x. This article has 41 citations and is from a highest quality peer-reviewed journal.

5. (caruso2024beyondwolframsyndromea pages 7-9): Valerio Caruso and Luciana Rigoli. Beyond wolfram syndrome 1: the wfs1 gene’s role in alzheimer’s disease and psychiatric sleep disorders. Unknown journal, Sep 2024. URL: https://doi.org/10.20944/preprints202409.2402.v1, doi:10.20944/preprints202409.2402.v1.

6. (morikawa2024comprehensiveoverviewof pages 11-13): Shuntaro Morikawa, Katsuya Tanabe, Naoya Kaneko, Nozomi Hishimura, and Akie Nakamura. Comprehensive overview of disease models for wolfram syndrome: toward effective treatments. Mammalian Genome, pages 1-12, Feb 2024. URL: https://doi.org/10.1007/s00335-023-10028-x, doi:10.1007/s00335-023-10028-x. This article has 7 citations and is from a peer-reviewed journal.

7. (hu2024isrinhibitionreverses pages 7-10): Rui Hu, Xiangyi Chen, Qiang Su, Zhaoyue Wang, Xushu Wang, Mengting Gong, Minglu Xu, Rongrong Le, Yawei Gao, Peng Dai, Zhen-Ning Zhang, Li Shao, and Weida Li. Isr inhibition reverses pancreatic β-cell failure in wolfram syndrome models. Cell Death and Differentiation, 31:322-334, Feb 2024. URL: https://doi.org/10.1038/s41418-024-01258-w, doi:10.1038/s41418-024-01258-w. This article has 9 citations and is from a domain leading peer-reviewed journal.

8. (wu2024novelwfs1variants pages 3-6): Lei Wu, Juan Zhang, Danjie Li, Zhongyun Zhang, Qicheng Ni, Rulai Han, Lei Ye, Yifei Zhang, Jie Hong, Weiqing Wang, Guang Ning, and Weiqiong Gu. Novel wfs1 variants are associated with different diabetes phenotypes. Frontiers in Genetics, Aug 2024. URL: https://doi.org/10.3389/fgene.2024.1433060, doi:10.3389/fgene.2024.1433060. This article has 0 citations and is from a peer-reviewed journal.

9. (dieguez2025wfs1e864kinhumans pages 41-44): Hernan H. Dieguez, Kevin Dubois, Elodie Reboussin, Cansu De Muijnck, Jérôme Sarniguet, Chantal Cazevieille, Stacy Alves, Julie Dégardin, Valérie Fradot, Serge Picaud, Stéphane Melik-Parsadaniantz, Maria Van Genderen, Andrea L. Vincent, Benjamin Delprat, and Elodie M. Richard. Wfs1<sup>e864k</sup> in humans and mice causes wolfram-like syndrome optic atrophy via early axonal mitochondrial dysfunction. BioRxiv, Oct 2025. URL: https://doi.org/10.1101/2025.10.13.682105, doi:10.1101/2025.10.13.682105. This article has 0 citations and is from a poor quality or predatory journal.

10. (jurca2024wolframsyndrometype pages 11-12): Alexandru Daniel Jurca, Larisa Bianca Galea-Holhos, Aurora Alexandra Jurca, Diter Atasie, Codruta Diana Petchesi, Emilia Severin, and Claudia Maria Jurca. Wolfram syndrome type i case report and review—focus on early diagnosis and genetic variants. Medicina, 60:1064, Jun 2024. URL: https://doi.org/10.3390/medicina60071064, doi:10.3390/medicina60071064. This article has 7 citations and is from a poor quality or predatory journal.

11. (jurca2024wolframsyndrometype pages 15-16): Alexandru Daniel Jurca, Larisa Bianca Galea-Holhos, Aurora Alexandra Jurca, Diter Atasie, Codruta Diana Petchesi, Emilia Severin, and Claudia Maria Jurca. Wolfram syndrome type i case report and review—focus on early diagnosis and genetic variants. Medicina, 60:1064, Jun 2024. URL: https://doi.org/10.3390/medicina60071064, doi:10.3390/medicina60071064. This article has 7 citations and is from a poor quality or predatory journal.

12. (morikawa2024comprehensiveoverviewof pages 7-9): Shuntaro Morikawa, Katsuya Tanabe, Naoya Kaneko, Nozomi Hishimura, and Akie Nakamura. Comprehensive overview of disease models for wolfram syndrome: toward effective treatments. Mammalian Genome, pages 1-12, Feb 2024. URL: https://doi.org/10.1007/s00335-023-10028-x, doi:10.1007/s00335-023-10028-x. This article has 7 citations and is from a peer-reviewed journal.

13. (morikawa2024comprehensiveoverviewof pages 17-19): Shuntaro Morikawa, Katsuya Tanabe, Naoya Kaneko, Nozomi Hishimura, and Akie Nakamura. Comprehensive overview of disease models for wolfram syndrome: toward effective treatments. Mammalian Genome, pages 1-12, Feb 2024. URL: https://doi.org/10.1007/s00335-023-10028-x, doi:10.1007/s00335-023-10028-x. This article has 7 citations and is from a peer-reviewed journal.

## Citations

1. liiv2024ercalciumdepletion pages 9-12
2. hu2024isrinhibitionreverses pages 7-10
3. morikawa2024comprehensiveoverviewof pages 11-13
4. patergnani2024thewolframlikevariant pages 6-9
5. caruso2024beyondwolframsyndromea pages 7-9
6. liiv2024ercalciumdepletion pages 1-2
7. patergnani2024thewolframlikevariant pages 1-6
8. jurca2024wolframsyndrometype pages 11-12
9. jurca2024wolframsyndrometype pages 15-16
10. morikawa2024comprehensiveoverviewof pages 7-9
11. morikawa2024comprehensiveoverviewof pages 17-19
12. https://doi.org/10.1038/s41467-024-50502-x
13. https://doi.org/10.1080/15548627.2024.2341588
14. https://doi.org/10.20944/preprints202409.2402.v1
15. https://doi.org/10.1007/s00335-023-10028-x
16. https://doi.org/10.1038/s41418-024-01258-w
17. https://doi.org/10.3389/fgene.2024.1433060
18. https://doi.org/10.1101/2025.10.13.682105
19. https://doi.org/10.3390/medicina60071064
20. https://doi.org/10.1101/2025.10.13.682105.
21. https://doi.org/10.1038/s41467-024-50502-x,
22. https://doi.org/10.1080/15548627.2024.2341588,
23. https://doi.org/10.20944/preprints202409.2402.v1,
24. https://doi.org/10.1007/s00335-023-10028-x,
25. https://doi.org/10.1038/s41418-024-01258-w,
26. https://doi.org/10.3389/fgene.2024.1433060,
27. https://doi.org/10.1101/2025.10.13.682105,
28. https://doi.org/10.3390/medicina60071064,